Today, Cytokinetics, Incorporated announced top-line results of BENEFIT-ALS. According to the company, BENEFIT-ALS did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo. Secondary efficacy analyses of the effect of tirasemtiv on respiratory function and other measures of skeletal muscle function produced mixed results. Read more at ow.ly/wbhCm.
Posted on: Fri, 25 Apr 2014 23:19:41 +0000
Trending Topics
Recently Viewed Topics
© 2015